4,7-二甲基吡唑并[5,1-C][1,2,4]三嗪-3-羧酸 | 175137-58-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并三嗪类
• 中文名称: 4,7-二甲基吡唑并[5,1-C][1,2,4]三嗪-3-羧酸
• 英文名称: 4,7-Dimethyl-pyrazolo[5,1-c][1,2,4]triazine-3-carboxylic acid
• 英文别名: 4,7-Dimethylpyrazolo[5,1-c][1,2,4]triazine-3-carboxylic acid
• CAS: 175137-58-3
• 化学式: C₈H₈N₄O₂
• mdl: MFCD00067873
• 分子量: 192.177
• InChiKey: JFCXJLMOHOXSTO-UHFFFAOYSA-N

物化性质

• 熔点：
  157-159°C
• 密度：
  1.57±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  80.4
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险类别码：
  R36/37/38,R
• 海关编码：
  2933990090
• 安全说明：
  S26,S36/37/39

反应信息

• 作为反应物：
  描述：

  4,7-二甲基吡唑并[5,1-C][1,2,4]三嗪-3-羧酸 、 3-amino-9-methyl-1-phenyl-6,7-dihydro-3H-[1,4]diazepino[6,7,1-hi]indol-4-one 在 O-[(ethoxycarbonyl)cyanomethyleneamino]-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以71%的产率得到4,7-Dimethyl-pyrazolo[5,1-c][1,2,4]triazine-3-carboxylic acid ((R)-9-methyl-4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-3-yl)-amide
  参考文献：
  名称：

  Synthesis, Structure−Activity Relationships, and Pharmacological Profile of 9-Amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1-hi]indoles:  Discovery of Potent, Selective Phosphodiesterase Type 4 Inhibitors

  摘要：

  The synthesis, structure-activity relationships, and biological properties of a novel series of; potent and selective phosphodiesterase type 4 (PDE4) inhibitors are described. These new aminodiazepinoindoles displayed in vitro PDE4 activity with submicromolar IC50 values and PDE4 selectivity vs PDE1, -3, and -5. Specifically, one compound (CI-1044, 10e) provided efficient in vitro inhibition of TNF alpha release from hPBMC and; hWB with IC50:values of 0.34 and 0.84 muM, respectively. This compound was found to exhibit potent in vivo activity in antigen-induced eosinophil recruitment in Brown-Norway rats (ED50 = 3.2 mg/kg po) and in production of TNF alpha in Wistar fats (ED50 = 2.8; mg/kg po). No emetic side effects at therapeutic doses were observed in ferrets.

  DOI：

  10.1021/jm000315p

文献信息

• Protease inhibitors
  申请人：Bondinell E William

  公开号：US20060052365A1

  公开（公告）日：2006-03-09

  This invention relates 4-amino-azepan-3-ones of formula (I) which are useful as protease inhibitors, particularly of cathepsin S, and as such are useful for preventing a number of diseases amongst which are atherosclerotic lesions and pulmonary diseases such as asthma and allergic reactions.

  这项发明涉及式（I）的4-氨基-氮杂七环-3-酮，它们可用作蛋白酶抑制剂，特别是卡特普辛S的抑制剂，并且作为预防多种疾病的有用药物，其中包括动脉粥样硬化病变和肺部疾病，如哮喘和过敏反应。
• Diazepinoindoles for the treatment of chronic obstructive pulmonary disease
  申请人：——

  公开号：US20020010175A1

  公开（公告）日：2002-01-24

  The present invention relates to the use of diazepinoindoles of the formula (I): 1 in which A is aryl or nitrogen-containing heteroaryl, and B is a hydroxyl or amino radical, for the treatment of chronic obstructive pulmonary disease.

  本发明涉及使用式(I)中的二氮杂并吲哚，其中A是芳基或含氮杂环芳基，B是羟基或氨基基团，用于治疗慢性阻塞性肺疾病。
• Use of diazepinoindoles for the treatment of chronic obstructive pulmonary disease
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1161950A1

  公开（公告）日：2001-12-12

  The present invention relates to the use of diazepinoindoles of the formula (I):    in which A is aryl or nitrogen-containing heteroaryl, and B is a hydroxyl or amino radical,    for the treatment of chronic obstructive pulmonary disease.

  本发明涉及式(I)的重氮吲哚的用途： 其中 A 是芳基或含氮杂芳基，B 是羟基或氨基、 用于治疗慢性阻塞性肺病。
• Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1161949A1

  公开（公告）日：2001-12-12

  The present invention relates to the use of diazepinoindoles of the formula (I):    in which A is aryl or nitrogen-containing heteroaryl, and B is a hydroxyl or amino radical,    for the treatment of chronic obstructive pulmonary disease.

  本发明涉及式(I)的重氮吲哚的用途： 其中 A 是芳基或含氮杂芳基，B 是羟基或氨基、 用于治疗慢性阻塞性肺病。
• Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1188438A1

  公开（公告）日：2002-03-20

  This invention relates to the use of a PDE4 inhibitor or a pharmacologically acceptable salt thereof for manufacturing a medicament for preventing or treating a disease associated with an excess in IL-12 production.

  本发明涉及使用 PDE4 抑制剂或其药理上可接受的盐制造药物，以预防或治疗与 IL-12 生成过多有关的疾病。